KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Current Liabilities (2016 - 2025)

TherapeuticsMD's Total Current Liabilities history spans 16 years, with the latest figure at $4.8 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 7.38% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $4.8 million, down 7.38%, while the annual FY2025 figure was $4.8 million, 7.38% down from the prior year.
  • Total Current Liabilities reached $4.8 million in Q4 2025 per TXMD's latest filing, down from $4.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $264.8 million in Q1 2022 to a low of $4.7 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $61.2 million, with a median of $14.4 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: soared 332.14% in 2022, then plummeted 92.7% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $252.9 million in 2021, then tumbled by 81.48% to $46.8 million in 2022, then plummeted by 85.37% to $6.9 million in 2023, then dropped by 24.63% to $5.2 million in 2024, then dropped by 7.38% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Total Current Liabilities are $4.8 million (Q4 2025), $4.9 million (Q3 2025), and $4.7 million (Q2 2025).